Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery

Shuo Li, Huaxiang Xu, Chuntao Wu, Wenquan Wang, Wei Jin, Heli Gao, Hao Li, Shirong Zhang, Jinzhi Xu, Wuhu Zhang, Shuaishuai Xu, Tianjiao Li, Quanxing Ni, Xianjun Yu, Liang LiuCancer 2019 · DOI

TL;DR

This study introduces a novel, easily accessible biomarker, the gamma-glutamyltransferase-to-albumin ratio (GAR), derived from routine liver function tests, to predict survival outcomes in patients undergoing radical surgery for pancreatic ductal adenocarcinoma (PDAC). The research demonstrates that a high GAR is an independent predictor of poorer overall and recurrence-free survival, and combining GAR with existing factors like TNM stage, CA19-9, and tumor differentiation significantly improves prognostic accuracy.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is notoriously aggressive, with a grim prognosis even after surgical resection. Current methods for predicting patient survival and recurrence primarily rely on postoperative histopathological features, which are not available pre-surgery. While some preoperative biomarkers like CA19-9 exist, they have limitations (e.g., non-secretory phenotypes). Clinicians face a challenge in accurately stratifying PDAC patients pre-operatively to guide treatment decisions and manage expectations. This paper aims to address this gap by identifying a readily available, preoperative biomarker that can better predict surgical outcomes.

Methods

The researchers conducted a retrospective analysis of 833 PDAC patients who underwent radical surgery. They calculated the gamma-glutamyltransferase-to-albumin ratio (GAR) using preoperative liver function test results. The optimal cut-off value for GAR was determined using Receiver Operating Characteristic (ROC) curve analysis. Survival analyses (overall survival - OS, and recurrence-free survival - RFS) were performed using univariate and multivariate Cox proportional hazard regression models. Kaplan-Meier curves were used to visualize survival differences between patient groups. To improve prognostic accuracy, they also developed and evaluated a combined prognostic model incorporating GAR with established factors like TNM stage, CA19-9, and tumor differentiation.

Datasets

The study utilized a dataset of 833 PDAC patients who underwent radical surgery at the Fudan University Shanghai Cancer Center between January 2010 and January 2017. This dataset was used for both the development and validation of the GAR biomarker and the combined prognostic model. No new benchmark datasets were introduced.

Key Insights and Ideas

  • GAR as a Proxy for Systemic Inflammation: The study suggests that GAR isn't just a measure of liver function but also a reflection of the patient's systemic inflammatory status. Elevated GGT is linked to oxidative stress, while low albumin can indicate inflammation and impaired liver reserve. Their combination, GAR, thus captures a complex interplay of host factors.
  • GAR's Independent Prognostic Power: Despite the complexity of PDAC, GAR emerged as a significant, independent predictor of both overall survival and recurrence-free survival, even after accounting for other known prognostic factors.
  • Context Matters for GAR: The prognostic value of GAR was most pronounced in patients without preoperative obstructive jaundice or severely impaired liver function. This highlights that while GAR is a valuable tool, its interpretation needs to consider the patient's overall clinical picture, particularly concerning liver health and biliary obstruction.
  • Synergy in Prognostic Modeling: The most impactful insight is that combining GAR with existing prognostic markers (TNM stage, CA19-9, tumor differentiation) significantly enhances predictive accuracy compared to using any single factor or even just the TNM stage alone. This points towards a more holistic approach to prognostication.

Key Results

  • The optimal cut-off value for GAR was determined to be 0.65.
  • Patients with a high GAR (>0.65) had significantly shorter median OS (7.4 months less) and RFS (4.8 months less) compared to those with a low GAR (≤0.65).
  • The 1, 2, and 3-year OS rates for high GAR patients were 75.2%, 36.2%, and 22.4%, compared to 88.7%, 51.4%, and 31.9% for low GAR patients, respectively (P < 0.001).
  • Similarly, 1, 2, and 3-year RFS rates for high GAR patients were 38.1%, 20.0%, and 15.4%, versus 57.8%, 31.6%, and 27.7% for low GAR patients (P < 0.001).
  • Multivariate analysis confirmed high GAR as an independent predictor of poorer OS (HR = 1.882) and RFS (HR = 1.552).
  • Combining TNM stage, GAR, CA19-9, and tumor differentiation resulted in the highest concordance index (C-index) for both OS (0.6923) and RFS (0.6559), outperforming TNM stage alone (OS: 0.6339, RFS: 0.6079).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design and Single Institution: The study was retrospective and conducted at a single center in China. This raises questions about the generalizability of the GAR cut-off value to other populations and institutions.
  • Focus on Resectable Cases: The analysis was limited to patients who underwent radical surgery, excluding those with unresectable PDAC or those receiving different postoperative treatments.
  • Limited Utility in Certain Conditions: The prognostic value of GAR was diminished or absent in patients with preoperative obstructive jaundice or severely impaired liver function.

Future work should involve larger, multi-center prospective studies to validate these findings and confirm the GAR cut-off value. Further research could also explore GAR's potential role in predicting response to neoadjuvant therapy, chemotherapy, and immunotherapy, as well as its utility in patients with unresectable disease.

Summary updated

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis. Many preoperative biomarkers can predict postoperative survival of PDAC patients. In this study, we created a novel ratio index based on preoperative liver function test, γ-glutamyltransferase-to-albumin ratio (GAR), and evaluated its prognostic value in predicting clinical outcomes of PDAC patients following radical surgery. We retrospectively enrolled 833 PDAC patients who had underwent radical surgery at our institution between January 2010 and January 2017. Patients were divided into two groups according to the cut-off value of GAR. Univariate and multivariate survival analysis between the groups were evaluated. TNM stage, GAR, preoperative serum carbohydrate antigen 19-9 (CA19-9) and tumor differentiation were combined to generate a more accurate prognostic model. The optimal cut-off value of GAR was 0.65. Significant correlations were found between GAR and tumor location, tumor size, vascular invasion, obstructive jaundice, biliary drainage and parameters of liver function test. Univariate and multivariate analysis showed that high level of GAR independently predicted poorer postoperative overall survival (OS, P < 0.001) and recurrence-free survival (RFS, P < 0.001). Subgroup analysis demonstrated that GAR was predictive of survival in patients without biliary obstruction or severely impaired liver function. In addition, integration of GAR, preoperative serum CA19-9, and tumor differentiation into TNM staging system could better stratify the prognosis for PDAC patients compared with TNM stage alone. Our study demonstrates that preoperative GAR is an independent prognostic factor for prediction of surgical outcomes in PDAC patients. Combination of TNM stage, GAR, preoperative serum CA19-9, and tumor differentiation can enhance the prognostic accuracy.
BibTeX
@inproceedings{li2019prognostic,
  author = {Shuo Li and Huaxiang Xu and Chuntao Wu and Wenquan Wang and Wei Jin and Heli Gao and Hao Li and Shirong Zhang and Jinzhi Xu and Wuhu Zhang and Shuaishuai Xu and Tianjiao Li and Quanxing Ni and Xianjun Yu and Liang Liu},
  title = {{Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.1002/cam4.1957},
}
Figure